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Chromosome translocations involving T cell receptor
(TCR) loci have been found in tumors from Ataxia tel-
angiectasia (AT) patients and in mouse Atm−/− thy-
moma, suggesting the involvement of V(D)J recombina-
tion in these malignancies. By introducing a RAG-1 de-
ficiency into Atm−/− mice in the presence of a TCR
transgene, we show that V(D)J recombination is critical
for thymoma development in these mice. Therefore, ab-
errant V(D)J recombination, normally suppressed by
Atm, facilitates tumorigenic events leading to cancer.
Because V(D)J recombination is dispensable for lym-
phomagenesis upon p53 deficiency, this study also indi-
cates that Atm and p53 function by distinct mechanisms
in suppressing thymoma.
Received February 17, 1999; revised version accepted April 1,
1999.
Chromosome translocations have been found in many
lymphoid malignancies, resulting in activation of proto-
oncogenes in those cells (Rabbitts 1994; Nowell 1997). In
many cases, the breakpoints of translocations involve
immunoglobulin or T cell receptor (TCR) loci, suggest-
ing a predisposition by these loci to the oncogenic
events. V(D)J recombination assembles immunoglobulin
and TCR gene segments via double-strand break (DSB)
intermediates and is active at immunoglobulin and TCR
loci during B and T cell development, respectively (Lewis
1994). It has long been hypothesized that errors in this
process provide a major source of chromosome translo-
cations in lymphoid malignancies (for review, see Dan-
ska and Guidos 1997; Kirsch and Lista 1997). However,
the molecules involved in regulating this process to sup-
press cancer proneness are not understood.
Ataxia telangiectasia (AT), caused by mutations in the
ATM gene, is a recessive chromosomal instability dis-
ease with pleiotropic phenotypes (Lavin and Shiloh
1997). AT patients have a high risk of cancer, particu-
larly lymphoid malignancies. Chromosome transloca-
tions involving the TCR locus occur at a high frequency
in AT T-lymphoid tumors (for review, see Taylor et al.
1996; Kirsch 1994). Furthermore, thymic lymphoma also
develops in Atm-deficient mice, and evidence for TCR-
associated rearrangements within tumors has been dem-
onstrated (Barlow et al. 1996; Elson et al. 1996; Xu et al.
1996). These observations suggest that the tumor sup-
pressor function of ATM acts through a mechanism in-
volving V(D)J recombination. To test this hypothesis, we
have analyzed the effect on tumorigenesis of inactivating
V(D)J recombination in Atm-deficient mice. Here, by in-
troducing a recombination activating gene (RAG)-1 de-
ficiency into Atm−/− mice, we show that V(D)J recom-
bination is a critical step in thymic lymphoma develop-
ment, thus identifying a critical role for Atm in
suppressing such tumorigenic events in the T-cell lin-
eage.
Results
Recombination-activating genes (RAG), Rag-1 and Rag-2
are required for the first step of V(D)J recombination,
that is, the initiation of DNA cleavage at recombination
sites (McBlane et al. 1995). Inactivation of either gene by
gene targeting results in complete inactivation of V(D)J
recombination in lymphocytes (Mombaerts et al. 1992;
Shinkai et al. 1992). If V(D)J recombination is involved
in the induction of thymoma in Atm-deficient mice,
blocking this process by Rag-1 deficiency should inhibit
tumorigenesis. Thus, Atm−/− mice were crossed onto a
Rag-1−/− background to inactivate V(D)J recombination,
and thymic lymphoma development was assessed. As
reported previously (Barlow et al. 1996), control Atm−/−
mice (n = 8) all died of thymic lymphoma with a mean
survival time of 4.8 months (Fig. 1). Similarly, all
Atm−/−Rag-1+/− mice (n = 5) died of thymic lymphoma
with a mean survival time of 4.7 months. Strikingly,
none of the Atm−/−Rag-1−/− mice (n = 9) developed thy-
mic lymphoma, nor were other tumors observed. Three
of the nine Atm−/−Rag-1−/− mice died of pneumonia at
5–6 months of age, likely because of impaired immune
function in Rag-1−/− mice, as similar infections were ob-
served in Atm+/+Rag-1−/− and Atm+/−Rag-1−/− litter-
mates. Not only was overt thymoma absent in
Atm−/−Rag-1−/− mice, thymocyte numbers averaged
<106 cells in these mice (not shown), further confirming
the absence of lymphoma. Because Atm−/−Rag-1−/− and
Atm−/−Rag-1+/− were littermates (Materials and Meth-
ods), mouse background differences other than indicated
deficiencies did not contribute to the inhibition of thy-
moma. Thus, prevention of V(D)J recombination by
Rag-1 deficiency blocked tumorigenesis in Atm-defi-
cient mice.
As a result of inactivating V(D)J recombination, Rag
deficiency blocks thymocyte development at the CD4/
CD8 double-negative (DN) stage, causing a decrease in
total thymic cellularity. It is conceivable that this indi-
rect effect on thymocyte number, rather than V(D)J re-
combination per se, could alter thymoma development
in Atm−/− mice. For example, reduction in thymus cel-
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lularity could reduce the size of target cell population for
secondary tumorigenic events and increase survival
time. However, reduced cellularity did not inhibit thy-
moma development in p53-deficient mice (Liao et al.
1998; Nacht and Jacks 1998). Also, Atm−/−Rag-1−/− mice
survived beyond 14 months of age with no sign of tumor
development (Fig. 1), indicative of a complete inhibition
of tumorigenesis rather than a delay. Another formal
possibility, however, is that tumorigenesis was inhibited
because of the blockage of thymocyte development. Al-
though normal thymocytes develop from DN to
CD4+CD8+ double-positive (DP), then to mature
CD4+CD8− or CD4−CD8+ single-positive (SP) cells, thy-
mocyte development in Atm−/−Rag-1−/− mice was ar-
rested at the DN stage as expected due to the Rag defi-
ciency (Fig. 2A). Although most Atm−/− thymic lympho-
mas are reported to consist of DP cells (Barlow et al.
1996; Elson et al. 1996; Xu et al. 1996), we have observed
a single case of DN Atm−/− thymoma, indicating that
these cells can give rise to Atm−/− thymoma (data not
shown).
To definitively address the possibility that indirect ef-
fects of inactivating V(D)J recombination contributed to
the inhibition of Atm−/− thymoma, we rescued thymo-
cyte development in Atm−/−Rag-1−/− mice by introduc-
ing a TCR transgene [TgN(TcrLCMV) (lymphocyte cho-
riomeningitis virus); Pircher et al. 1989]. Transgenic ex-
pression of the prerearranged TCRa and TCRb genes in
Rag-1−/− thymocytes induces thymocyte development in
the absence of V(D)J recombination. Similar to the re-
sults in previous studies (Pircher et al. 1989; Shinkai et
al. 1993), expression of LCMV–TCRa and TCRb genes in
Atm−/−Rag-1−/− thymocytes rescued thymocyte devel-
opment to DP and SP stages (Fig. 2A) and restored thy-
mus cellularity to the normal level (not shown). To en-
sure that transgenic TCR-expressing thymocytes were
positively selected by matched major histocompatibility
complex (MHC) molecules, Atm−/−TCR+Rag-1−/− mice
were screened for histocompatibility. Two subtypes of
H-2D MHCs, H-2Db and H-2Dd occur in mice in this
study due to their mixed genetic background. Transgenic
LCMV–TCR-expressing thymocytes survive in the pres-
ence of the H-2Db subtype (Pircher et al. 1989). FACS
analysis showed that all mice included in this study
were H-2Db positive (Fig. 2B). The b-chain segment Vb8.1
of the transgene also reacts with the Mlsa superantigen,
which can lead to the elimination of mature SP but not
Figure 2. Rag-1−/− thymocyte differentiation is rescued by a
TCR transgene. (A) CD4/CD8 expression was analyzed by
FACS (Materials and Methods). Atm−/−Rag-1−/− thymocytes
(Atm−/−R1−/−) are blocked at the CD4−CD8− DN stage compared
to wild-type (WT) thymocytes. Expression of LCMV–TCR trans-
genes in Atm−/−Rag-1−/− thymocytes (Atm−/−TCR+R1−/−) in-
duced a CD4+CD8+ DP population. The Atm−/−TCR+ thymo-
cyte population is shown as a control. TCR+ thymocytes have
the same profile as those from Atm−/−TCR+ mice (not shown).
(B) Lack of positive thymic selection is not a factor in thymoma
inhibition. Most of the Atm−/−TCR+Rag-1−/− mice are H-2Db
positive, and have mature T cells in peripheral blood.
Atm−/−TCR+R1−/− mice were screened for the presence of the
H-2Db MHC molecule and the TCR component CD3 using
PBLs (Materials and Methods). Profiles of PBLs from C57BL6
and DBA2 mice are shown as positive and negative controls for
the presence of H-2Db, respectively. One typical profile of the
seven Atm−/−TCR+R1−/− PBLs is shown, which confirms H-2Db-
positive and CD3-positive (mature) T cells. An Atm−/−R1−/−
PBL profile serves as the negative control for CD3 expression of
mature T cells.
Figure 1. Rag-1 is required for thymic lymphoma development
in Atm−/− mice. Tumor-free survival of mice is plotted with
time. Each data point represents the sacrifice or death of a ter-
minally ill mouse. A drop in percentage reflects the sacrifice or
death of a mouse with thymoma. As with Atm−/− mice (h;
n = 8), 100% of the Atm−/−Rag-1+/− mice (L; n = 5) developed
thymic lymphoma. The mean survival time was 4.8 months for
Atm−/− mice and 4.7 months for Atm−/−Rag-1+/− mice. All
Atm−/−Rag-1−/− mice (s; n = 9) died or were sacrificed with no
overt thymic lymphoma or other tumors. The mean survival
time was 9 months, comparable to Rag-1−/− mice housed under
the same conditions. Three of the nine Atm−/−Rag-1−/− mice
died of pneumonia at 5–6 months with no sign of thymic lym-
phoma. Mouse food containing antibiotics was used to treat one
Atm−/−Rag-1−/− mouse of this data set with similar symptoms.
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DP cells (Pircher et al. 1989). Because of the DP origin of
Atm−/− tumors, the Mlsa antigen (if present) should not
affect the target cell population (DP). Nevertheless, to
test whether negative selection had affected the T-cell
population in Atm−/−TCR+Rag-1−/− mice, PBLs were
analyzed for the presence of a mature CD3+ T cells. All
Atm−/−TCR+Rag-1−/− PBL samples contained mature
CD3+ T cells, indicating that negative selection did not
delete this population and further supporting a matched
MHC type. As a control, mature cells were absent from
Atm−/−Rag-1−/− mice in which thymocyte development
was blocked (Fig. 2B). Therefore, the presence of the TCR
transgene did not cause deletion of critical subsets of
thymocytes that could be possible targets for tumorigen-
esis.
Despite the restoration of thymocyte differentiation in
Atm−/−TCR+Rag-1−/− mice, however, thymic tumors
were not observed in these mice. Control littermate
Atm−/−TCR+Rag-1+/− mice (n = 12) all died of thymic
lymphoma at a time similar to that of Atm−/− mice
(n = 8; mean survival of 5.0 months and 4.8 months, re-
spectively). However, Atm−/−TCR+Rag-1−/− mice (n = 9)
did not develop tumors. All mice lived beyond the mean
Atm−/− survival time of 5 months with no evidence of
thymoma development (Fig. 3). The thymuses of several
mice that died of infections (mean survival, 8 months;
range, 6–9 months) were normal compared to age-
matched controls. Three mice are currently healthy at
8–9 months. Therefore, an intact V(D)J recombination
pathway is critical for the induction of thymic lym-
phoma in Atm-deficient mice. By extension, these re-
sults implicate Atm in the regulation or checkpoint con-
trol of thymocyte V(D)J recombination.
Discussion
Chromosomal translocations are the most common ge-
netic alterations in human lymphoid malignancies (Rab-
bitts 1994). The presence of a high frequency of antigen
recognition gene translocations suggests that V(D)J re-
combination is involved in most of these cases (Nowell
1997). Recent in vitro studies have shown that the RAG
proteins can mediate DNA transposition-like events,
suggesting that RAG proteins may have a role in onco-
genic translocations (Agrawal et al. 1998; Hiom et al.
1998). The Atm-deficient mouse model accurately re-
flects the occurrence of such translocations, which de-
velop in human AT T-cell neoplasms (Taylor et al. 1996).
Similar translocations are also observed in non-AT lym-
phoid tumors (albeit at a lower frequency), indicating a
general underlying mechanism. Our study shows that
V(D)J recombination can drive tumorigenic events lead-
ing to lymphomagenesis. Moreover, these results further
link Atm to a tumor suppression mechanism that is tied
to V(D)J recombination, as aberrant V(D)J recombinase
activity is normally inhibited or eliminated in mouse
thymocytes in the presence of Atm. Thus, loss of Atm
function predisposes to lymphoid malignancy. These
findings represent an inroad to the molecular under-
standing of the respective V(D)J oncogenic and Atm tu-
mor suppression mechanisms. In addition, because early
death of Atm-deficient mice from thymic lymphoma
normally hampers prolonged study of any neurological
defects of AT in these mice, Atm-deficient mice in
which thymomagenesis is inhibited (in a Rag-1-deficient
background) will facilitate further study of this disease.
Although no overt ataxia was observed in mice of our
study, close examination may yield further insight.
Role of ATM in V(D)J recombination fidelity
Several possible explanations exist for Atm’s role in sup-
pressing chromosomal translocations. First, ATM acts in
cell cycle checkpoints to signal DSBs at G1, S, and G2/M
phases (Kastan et al. 1992; Meyn 1995; Shiloh and Rot-
man 1996). Premature entry into S phase or mitosis in
Atm-deficient cells with unrepaired DSBs could promote
recombination by erroneous, nonhomologous end join-
ing leading to translocations (Elledge 1996; Paulovich et
al. 1997). Second, Atm has a role in meiotic chromosome
synapsis and recombination (Plug et al. 1997). It is pos-
sible that Atm participates in the synaptic structures
that orchestrate V(D)J recombination and prevent inter-
chromosomal recombination. Failure in this orchestra-
tion would lead to translocation. The level of hybrid
TCR genes generated by interlocus recombination is 10-
to 100-fold higher in human AT lymphocytes compared
with normal lymphocytes (Lipkowitz et al. 1990; Ko-
bayashi et al. 1991). Third, Atm deficiency could affect
chromatin organization and TCR locus accessibility, re-
sulting in overexuberant recombination at these sites
(Kirsch 1994). DSBs observed in AT cells are present
more frequently as chromatin breaks suggesting that
ATM may participate in managing chromatin structure
at some DSBs (Pandita and Hittelman 1992). Fourth, it is
possible that Atm functions in detecting and eliminating
cells with illegitimate V(D)J recombination products by
inducing apoptosis. In mouse CNS development, Atm is
Figure 3. V(D)J recombination is required for Atm-deficient
thymoma. All Atm−/− mice (h; n = 8) and Atm−/−TCR+Rag-1+/−
mice (L; n = 12) died of thymic lymphoma with a mean sur-
vival time of 4.8 and 5.0 months, respectively. Of the
Atm−/−TCR+Rag-1−/− mice shown (s; n = 9), 6 died of infec-
tions at 6–9 months (mean survival, 8 months) with no sign
of thymic lymphoma. Others are currently alive at 8 months
with no sign of lymphoma. Because Atm−/−TCR+Rag-1+/− and
Atm−/−TCR+Rag-1−/− mice are from the same cross, genetic
background does not contribute to the observed difference.
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required for apoptosis after irradiation-induced DNA
damage (Herzog et al. 1998), although some controversy
surrounds the issue of whether Atm is involved in a
similar response in thymocytes (Xu and Baltimore 1996;
Barlow et al. 1997; Westphal et al. 1997). Finally, a DSB
repair defect distinct from cell cycle checkpoint defects
has been suggested in AT cells (Jeggo et al. 1998). Higher
than normal levels of chromosome breaks and rearrange-
ments were observed in noncycling AT cells upon irra-
diation (IR). Further experiments are required to distin-
guish whether one or more of these mechanisms has a
role in Atm-mediated tumor suppression.
ATM and p53 suppress thymoma by distinct
mechanisms
Previous evidence supports the hypothesis that ATM
acts upstream of p53 in signaling IR-induced DNA dam-
age in fibroblasts. Human AT cells are deficient in up-
regulating p53 (Kastan et al. 1992), and ATM acts as a
Ser/Thr protein kinase in phosphorylating and activat-
ing p53 at Ser-15 upon irradiation (Banin et al. 1998;
Canman et al. 1998). The fact that both Atm- and p53-
deficient mice develop thymoma was suggestive that
these factors function in the same pathway in thymo-
cytes as well. However, our data indicate different
mechanisms for Atm and p53 tumor suppression in
mouse thymocytes. We (Liao et al. 1998) and others
(Nacht et al. 1998) examined thymoma development pre-
viously in p53-deficient mice using a similar strategy as
described here for Atm. Thymomas developed in p53-
deficient mice in the absence of V(D)J recombination
(inhibited by a deficiency of Rag-1 or Rag-2), although
longer latencies were observed. We showed further that
thymomas developed in a Rag1−/−/TCR+ background
without effect on frequency and with no increased la-
tency. Furthermore, the major aberration detected in
p53-deficient thymomas was aneuploidy (Liao et al.
1998), whereas chromosome translocations, including
those associated with TCR chromosomes, are common
in Atm-deficient thymomas (Barlow et al. 1996; Liao et
al. 1998). No such translocations were observed in p53-
deficient thymomas (Liao et al. 1998).
The observation that Atm and p53 function by distinct
mechanisms in thymocytes is consistent with a previous
report that p53 and Atm cooperate in thymoma suppres-
sion. Thymoma development is accelerated in p53/Atm
doubly deficient mice relative to either deficiency alone,
indicating that Atm and p53 function in distinct comple-
mentary pathways (Westphal et al. 1997). Together,
these data suggest that there may be multiple mecha-
nisms for ATM tumor/checkpoint regulation. Although
its function in p53 activation is important for cell cycle
arrest upon irradiation-induced DNA damage in some
cell types, ATM appears to maintain the fidelity of DNA
recombination via a different pathway. Given the link
demonstrated here between Atm and V(D)J-driven lym-
phoma suppression, further molecular studies will be re-
quired to determine the extent to which this function
represents a new activity for Atm.
Materials and methods
Mice
Homozygous Atm−/− mice are infertile (Barlow et al. 1996; Elson et al.
1996; Xu et al. 1996). Thus, Atm+/− mice [129/SvEv-C57BL/6J; kindly
provided by A. Wynshaw-Boris (Barlow et al. 1996)] were bred with Rag-
1−/− mice (C57BL/6J-sv/129; Jackson Labs) to generate Atm+/−Rag-1+/−
(F1) mice. F1 mice were backcrossed to Rag-1
−/− mice to generate both
Atm+/−Rag-1−/− and Atm+/−Rag-1+/− mice. These mice were crossed fur-
ther to generate Atm−/−Rag-1−/− and Atm−/−Rag-1+/− mice. TgN(TcrL-
CMV) mice (C57BL/6J-DBA2; Jackson Labs) were bred with Atm+/−Rag-
1−/− mice to generate Atm+/−TCR+Rag-1+/− mice, which were further
bred with Atm+/−Rag-1−/− mice to generate Atm−/−TCR+Rag-1−/− mice.
PCR primers were designed for genotyping Atm−/− mice. Primer pairs
Atm-F2 (58-AAACCGACTTCTGTCAGATGTTGC-38) and Atm-B2 (58-
TTTGCAGGAGTTGCTGAGCG-38) were used to identify the wild-type
Atm allele. Atm-F (58-GACTTCTGTCAGATGTTGCTGCC-38) and
Atm-Neo (58-GGGTGGGATTAGATAAATGCCTG-38) were used to
identify the knockout allele in 35 cycles of 94°C for 1 min, 55°C for 1
min, and 72°C for 1 min. The Atm-F2 and Atm-B2 pair generates a 152-bp
PCR product, and the Atm-F and Atm-Neo pair generates a 441-bp PCR
product. PCR was used for genotyping Rag-1 and TgN(TcrLCMV) mice as
described previously (Liao et al. 1998). Mice were maintained under ster-
ile conditions with autoclaved microisolator cages and autoclaved water,
food, and bedding.
Immunophenotyping
Thymocytes were isolated as described previously (Liao et al. 1998) and
counted using a hemocytometer. Peripheral blood was collected from tail
vein into heparin (Elkins-Sinn, Inc.) containing tubes. Red blood cells
were lysed to obtain peripheral blood lymphocytes (PBLs) using the Uno-
pette solution (Becton-Dickinson). CD4, CD8, CD3, a/b or g/d TCR
markers were stained as described previously using antibodies from
PharMingen (Liao et al. 1998). H-2Db in PBLs was detected using FITC-
conjugated anti-mouse H-2Db and FACS analysis. PBLs were treated with
anti-mouse CD16/CD32 (PharMingen) before anti-H-2Db staining to
block nonspecific binding to Fc receptors.
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Note added in proof
A similar inhibition of tumorigenesis has been observed in Atm-
deficient/RAG-deficient mice in studies by Y. Xu (pers. comm.;
for review, see Xu, Y. 1999. ATM in lymphoid development and
tumorigenesis. Adv. Immunol. 72: 179–189.)
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